Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC) Meeting Abstract

  

Authors:	Meric-Bernstam, F.; Tannir, N.; Harding, J.; Voss, M.; Mier, J.; DeMichele, A.; Munster, P.; Patel, M.; Iliopoulos, O.; Owonikoko, T.; Whiting, S.; Orford, K.; Bennett, M.; Carvajal, R.; McKay, R.; Fan, A.; Telli, M.; Infante, J.
Abstract Title:	Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC)
Meeting Title:	28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Journal Title:	European Journal of Cancer
Volume:	69
Issue:	Suppl. 1
Meeting Dates:	2016 Nov 29-Dec 2
Meeting Location:	Munich, Germany
ISSN:	0959-8049
Publisher:	Elsevier Inc.
Date Published:	2016-12-01
Start Page:	S12
End Page:	S13
Language:	English
ACCESSION:	WOS:000390503500021
PROVIDER:	wos
DOI:	10.1016/S0959-8049(16)32626-0
Notes:	Meeting Abstract: 26 -- 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 29-DEC 02, 2016 -- Munich, GERMANY -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/104628